Dr. Joël Claveau

Dermatologist, Ville de Québec, QC

Dr. Joël Claveau is a dermatologist, specialized in the diagnosis and treatment of Melanoma and Skin Cancers, and an Associate Professor with the Department of Medicine at Laval University where he completed his Medical Study and Internal Medicine training. He did his residency in Dermatology at McGill University and subsequently worked at the Melanoma Clinic at the Royal Victoria Hospital in Montreal, Quebec. He is a diplomat of the American Board of Dermatology and is a member of a number of Medical Societies including the American Academy of Dermatology and the International Dermoscopy Society. He has received awards including
Honorary Member of La Société Française de Dermatologie, the Dermatologist’s Volunteer Award of the Canadian Dermatology Association (CDA) for his work on the prevention of skin cancers and the CDA
Symposium of the year at two occasions (Dermoscopy).

Since 1996, he has been the Director of the Melanoma and Skin Cancer Clinic at Le Centre Hospitalier Universitaire, Hôtel-Dieu de Québec, and worked in
Public Health for the province of Québec especially on the new Tanning Bed Legislation. He participated to the publication of papers in peer-review journals including work on melanoma, skin cancers and sunscreens. He is actively involved in a various Continuing Medical Education events and investigator in many clinical trials on advanced and metastatic melanoma.

2:05 PM - 2:35 PM

FRI Apr 19

Reviewing the latest advancements in the treatment landscape for advanced cutaneous squamous cell carcinoma

This will be a case-based, interactive discussion with Dr. Claveau.

Learning Objectives:

  1. Strategies for optimizing the recognition and diagnosis of advanced Cutaneous Squamous Cell Carcinomas (cSCCs), along with the optimal referral pathways
  2. Examine the importance of a multi-disciplinary management of patients with advanced Cutaneous Squamous Cell Carcinoma, emphasizing its critical role in enhancing patient outeomes
  3. Discuss the critical role of anti-PD-L1 therapy in the comprehensive management of complex Cutaneous Squamous Cell Carcinoma cases, focusing on its efficacy, safety profile, and impact on patient outcomes.

11:25 AM - 11:55 AM

SAT Apr 20

Adjuvant Therapy of Melanoma: update 2024

Brief session description:
In this interactive session, we will review the actual staging classification for melanoma and underline high risk groups. Major innovations have recently been made in the management of high risk stage III patients with the use of immunotherapy and targeted therapy. Adjuvant anti-PD1 immunotherapy is now indicated in Stage IIB and IIC patients and recent data on these treatment options will be presented including the side effect profile.


  1. Understand the importance of Adjuvant therapy for High-risk melanoma
  2. Review Adjuvant treatment options for Stage III and present the role of immunotherapy in high-risk Stage II patients
  3. Emphasis the role of dermatologists in the diagnosis, counselling and follow-up of melanoma patients